IGF-1 DES
Fat LossTruncated IGF-1 analog / researchExperimental
IGF-1 lacking the first three amino acids, with reduced IGFBP binding and higher local potency in research models. Not FDA-approved. WADA S2.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Research-dependent
- Last updated
- 8/23/2026
- Targets
- IGF-1 receptor
Overview
IGF-1 lacking the first three amino acids, with reduced IGFBP binding and higher local potency in research models. Not FDA-approved. WADA S2.
Protocol
- Dosage Range
- Not established as a drug
- Frequency
- Research-dependent
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
N-terminal truncation lowers IGFBP affinity so more peptide is free to activate IGF-1R, often used locally in animal muscle studies.
Targets
IGF-1 receptor
Studies
- DES(1-3)IGF-1 biochemistry— Journal/year not available
Benefits
Local IGF-1R research tool
Potential Side Effects
- Hypoglycemia risk
- Unknown human safety
References
- PMID 1699585External link · Year —
- WADA Prohibited List 2026External link · Year —